Egis favipiravir drug licensed for COVID-19 treatment
A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licensed for the treatment of COVID-19 by the National Institute of Pharmacy and Nutrition (OGYÉI), the institute said on Saturday according to a report by state news wire MTI.
The license was issued in an expedited procedure.
The drug, which Egis started developing in April, could be used to treat coronavirus patients from mid-January.
Favipiravir is the second drug, after remdesivir, that has been licensed by the OGYÉI to treat COVID-19 patients.
Hungary Gasoline Prices 3% Over Regional Avg
Hungary to Address Future of Cohesion Policy During EU Presi...
120,000 Guest Workers Employed in Hungary
Budapest Airport Wins 'Best Airport in Eastern Europe' for 1...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
